FDA adds optic neuropathy warning to all GLP-1 drugs; Tandem Mobi cleared to run tubeless; survodutide meets cardiovascular safety bar

Listen to this post
read by AI voices · all episodesThe Food and Drug Administration (FDA) on Nov. 9 required all GLP-1 receptor agonist labels to warn of nonarteritic anterior ischemic optic neuropathy (NAION).
Tandem Diabetes Care said the FDA cleared its Mobi automated insulin delivery system for tubeless use. Survodutide met cardiovascular noninferiority in SYNCHRONIZE-CVOT, and CagriSema at lower doses produced about 21% weight loss in REDEFINE 9.
- FDA Nov 9, 2026The Food and Drug Administration (FDA) said Nov. 9 it is requiring all GLP-1 receptor agonist labels to add nonarteritic anterior ischemic optic neuropathy (NAION) to Warnings and Precautions. Across 126 randomized trials, NAION occurred at 6.4 events per 100,000 person-years with GLP-1 drugs versus 3.8 with comparators; in a Sentinel cohort the hazard ratio was 1.43 (95% CI 1.02 to 2.01) versus DPP-4 inhibitors and 1.19 (95% CI 0.91 to 1.54, not significant) versus SGLT2 inhibitors. The FDA advises referring suspected cases to an ophthalmologist and considering stopping the drug in patients who develop NAION.Sources: FDA, Pharmacy Times
- FDA Nov 13, 2026Tandem Diabetes Care said Nov. 13 that the Food and Drug Administration (FDA) cleared Mobi for use as what the company called the world's first and only tubeless automated insulin delivery system, with a tubeless infusion set cleared for up to 7 days of wear. Control-IQ+ is indicated for type 1 diabetes from age 2 and type 2 diabetes from age 18; U.S. launch is planned for the first half of 2027. MedTech Dive reported Nov. 11 that Tandem began recalling more than 80,900 Mobi pumps over false occlusion alarms, with 230 reported adverse events requiring medical intervention or hospitalization.
- Research Nov 9, 2026In the phase 3 trial funded by Boehringer Ingelheim and published Nov. 9 in The Lancet, the primary composite of cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, ischemia-related coronary revascularization or heart failure event occurred in 136 of 3,671 patients given survodutide (3.6 mg or 6.0 mg weekly, pooled; 3.7%) and 76 of 1,836 given placebo (4.1%), hazard ratio 0.89 (95% CI 0.67 to 1.18). That met noninferiority but was not a significant reduction. The authors said survodutide was not associated with increased risk for the primary end point.Source: The Lancet
- Research Nov 14, 2026In the phase 3b trial of 309 adults with overweight or obesity at 24 sites in Canada, France, Germany, the United Kingdom and the United States, published Nov. 14 in The Lancet Diabetes and Endocrinology, body weight fell 20.7% with cagrilintide-semaglutide 1.7 mg each and 21.0% with 1.0 mg each, versus 2.0% with placebo. At least 5% weight loss was reached by 95.1% on the 1.7 mg dose versus 33.4% on placebo. The authors said the lower doses were superior to placebo.
- Research Nov 9, 2026In two randomized trials in adults with moderate to severe obstructive sleep apnea and excess weight, one in CPAP users, the once-daily oral GLP-1 drug group had about 18 fewer breathing interruptions per hour of sleep at 52 weeks versus about five fewer with placebo, according to the American Heart Association (AHA). Eli Lilly said the apnea-hypopnea index fell 21.1 events per hour without positive airway pressure and 18.3 with it. Body weight fell about 10% to 11% with orforglipron. Nausea, diarrhea and constipation were most common. The results were presented Nov. 9 and published in JAMA.Sources: American Heart Association, Eli Lilly
- Research Nov 12, 2026In the randomized trial of 865 women at risk of gestational diabetes in Australia, Ireland, Spain and the United Kingdom, published Nov. 12 in The Lancet Digital Health, personalized mobile health coaching spanning pregnancy and an extended postpartum period did not reduce mean maternal BMI at 12 months compared with usual care. Mean BMI change did not differ between groups, the authors said.Source: The Lancet Digital Health
The weekly innovation roundup for endocrinology, published every Sunday for the week before; every item links to its sources. Latest endocrinology news · All specialties